

1. Abstract Title:

Real-world three-year outcome in patients with non-valvular atrial fibrillation in the era of treatment with direct oral anti-coagulants: the ASSAF-K registry

2. Abstract Category (from attached list):

08 Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias

3. Keywords (between 1 and 3 from attached list):

**Epidemiology
Atrial fibrillation
Anticoagulants**

4. Abstract Body (maximum 1900 characters, not including spaces):

Background

Recently anticoagulant therapy with direct oral anticoagulants (DOACs) for atrial fibrillation (Af) has been dramatically changed. However, the real-world status and outcome of the patients with Af were not clarified.

Methods

The ASSAF-K, a prospective, multi-center, observational study, was conducted from 2013. The primary endpoints were to clarify epidemiologic characteristics, status of treatment with anticoagulants, three-year outcomes, and adverse events.


Results

The analyzed number was 3839 enrolled in 105 institutes (26 hospitals and 79 clinics). Mean age was 72.7 ± 10.1 years, proportion of men was 65.4%. CHADS₂-Vasc score and HAS-BLEAD were 3.00 ± 1.59 , 2.23 ± 1.06 , respectively. The risk factors of composite endpoint (all-cause death, severe adverse events, cerebral hemorrhage and stroke) were age (hazard ratio [HR] 1.062; 95% confidence interval [CI], 1.044-1.080, history of heart failure (HR: 1.274; 95% CI, 1.014-1.601), stroke (HR: 1.621; 95% CI 1.277-2.058). Three year-event-free-rate in the DOACs, warfarin, and without anti-coagulants were 91.5%, 87.3%, and 86.6%, respectively. The event rate in the DOACs was significantly lower than that in warfarin ($P=0.002$) (figure). Severe adverse events were significantly ($P=0.016$) lower in DOACs than those in warfarin.

Conclusions

The ASSAF-K registry have demonstrated the real-world Af patient characteristics and three-year outcome, suggesting that treatment with DOACs for Af patients was safe and beneficial.

(1292 words)



5. Clinical Implications (complete the following sentence):
My study will help enable cardiovascular clinicians to manage effectively and safely the patients with atrial fibrillation with direct oral anticoagulants.

6. Authors (first name, last name, email address):
Yutaka Hatori; yutaka@hatori.or.jp
Hiroyuki Sakai; info@sakai-iin.com
Nobuo Hatori; hatnobu@pa2.so-net.ne.jp
Makoto Shimizu; makotoshimizuyaizu@gmail.com
Atsuo Namiki; namikiatsuo@icloud.com
Masaomi Kuwajima; mdkuwajima@aol.com
Nobuo Toyosaki; toyo0719@tj9.so-net.ne.jp

Tomoyuki Kunishima; tkuni@mte.biglobe.ne.jp

Naoki Sato;

On behalf of ASSAF-K investigators

7. Responsible Institutions (between 1 and 2 institutions, include name, city, country):

Hatori Clinic, Kawasaki, Japan

8. Lead Investigator (name of senior author or primary investigator):

Yutaka Hatori